Hepatitis C Treatment by Primary Care Teams in Inner-City Clinics: A Prospective Cohort Study

Nouch S¹,², Gallagher L¹, Erickson M³, Grewal A², Kleban H¹, Quesnelle J¹, Persaud S¹, Kason D¹, Pare D¹,², Knebel L¹,², Viljoen M¹, Zhang W³, Bacani N³, Sereda P³, Shoveller J³, Hall D¹,², Norbury M¹,², Barrios R¹,²,³, Hull M¹,²,³

¹ Vancouver Coastal Health Authority, Vancouver, Canada.
² University of British Columbia, Vancouver, Canada.
³ BC Centre for Excellence in HIV/AIDS, Vancouver, Canada.

Disclosures

• Dr. Susan Nouch has no disclosures.

• This study was entirely supported by a grant from the Vancouver Coastal Health Research Institute.
Background/aims

- HCV direct acting antiviral (DAA) therapies highly effective, but limited real-world data in marginalized populations.
- Efforts to scale-up treatment of HCV in these populations including persons who inject drugs (PWID), necessitates integrated models of care.
- Prescribing restricted to specialists in many regions
- Study Aim: To determine the effectiveness of an HCV treatment model, implemented by family physicians working in interdisciplinary teams within inner-city primary care clinics.

Methods

- Inner-City HCV Treatment Programs:
  - Located within 3 Vancouver primary care/addiction clinics
  - Family physician treaters/prescribers with HCV and addiction expertise along with interdisciplinary teams
  - Embedded support from Infectious Disease Consultant
  - Optional group/peer support
- Prospective cohort of individuals undergoing HCV therapy since Sept 2015
  - Baseline questionnaire including questions on substance use
- Study Endpoints:
  - SVR 12: HCV RNA undetectable 12 weeks following the end of therapy
  - LTFU: No follow-up HCV visit within 10 weeks of SVR 12 due date
- Analysis: Multivariate regression analysis for factors associated with LTFU
Results

- N of 135: due for SVR 12 before June 1st, 2017
- 76% male, median age 53 (IQR 47-60), 36% cirrhosis, 18% treatment experienced, 70% genotype 1
- 74% IDU ever, 24% injected month prior to treatment, 53% were on ORT
- Of those on ORT, 67% received ORT at HCV treating site
- 89% not seen directly by specialist MD for HCV in year prior to treatment

24% Lost to Follow-Up*
(*42% evidence engaged in care but no bloodwork done)

Participants with ORT at treating clinic less likely to be LTFU (AOR 0.18; 95% CI 0.05 – 0.61)

No documented cases of early reinfection (before SVR 12)
Conclusions/implications

- HCV treatment in the primary care setting by interdisciplinary teams including family physicians can be successful in inner-city populations in the era of DAAs

- Integrating opiate replacement therapy at HCV treatment site associated with lower rate of LTFU

- Improving follow-up is important:
  - To document SVR outcomes and reinfection
  - To ensure appropriate follow-up continues for those with cirrhosis
  - To continue engagement in primary care/addiction care

We FIGHT for those we LOVE and LOST!